Alpha TAU Medical fully supports World Cancer Day 2017 (Saturday, February 4), and is inspired by its efforts to unite the world against this disease; to target misinformation, to raise awareness, and to reduce stigma. Under the campaign theme “We can. I can.” World Cancer Day represents a unique opportunity to draw attention to what can be done to address cancer, save millions of avoidable deaths and, in turn, support global economic growth and development.
Alpha Tau Medical has received IRB approval from IRST (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), in Italy for clinical trials with its Alpha DaRT (Diffusing Alpha–emitters Radiation Therapy) technology for the treatment of Squamous Cell Carcinoma (SCC) in skin cancer. The company is also in the process of finalizing additional protocols for clinical trials in Colorectal and Prostate cancers. Initial trials are due to start within the next few months.
Alpha Tau Medical has initiated its first clinical trials with its Alpha DaRT (Diffusing Alpha–emitters Radiation Therapy) technology for the treatment of Squamous Cell Carcinoma (SCC) in Head, Neck and Skin at the Rabin Medical Center, Petah Tikva outside Tel Aviv.
The company is in the process of starting additional clinical trials in prostate cancer, breast cancer, colorectal cancer, gynecological cancer and pancreatic cancer.
The Alpha DaRT technology enables the possib